US 5440021A
· Chuntharapai et al.
· 1995
[cited by applicant]
US 5795965A
· Tsuchiya et al.
· 1998
[cited by applicant]
US 7183076B2
· Arathoon et al.
· 2007
[cited by applicant]
US 8562991B2
· Igawa et al.
· 2013
[cited by applicant]
US 8945552B2
· Bachner et al.
· 2015
[cited by applicant]
US 9168300B2
· Gurney et al.
· 2015
[cited by applicant]
US 9562109B2
· Von Kreudenstein et al.
· 2017
[cited by applicant]
US 9562110B2
· Zhou et al.
· 2017
[cited by applicant]
US 9688758B2
· Wranik et al.
· 2017
[cited by applicant]
US 9856319B2
· Ghayur et al.
· 2018
[cited by applicant]
US 20220251222A1
· Spangler et al.
· 2022
[cited by applicant]
JP 2014534198
· 2014
[cited by applicant]
JP 2016514463
· 2016
[cited by applicant]
WO WO2013005958
· 2013
[cited by applicant]
WO WO2013055958
· 2013
[cited by applicant]
WO WO2013055958A1
· 2013
[cited by examiner]
WO WO2014084607
· 2014
[cited by applicant]
WO WO2018072025
· 2018
[cited by applicant]
WO WO2018191746A1
· 2018
[cited by applicant]
Xu et al. “Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system.” mAbs 2015. 7:1, 231-242. (Year: 2015).
[cited by examiner]
Yusakul et al. “Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity.” Biosci., Biotechnol., Biochem. 2016, 80;7:1306-1312. (Year: 2016).
[cited by examiner]
Brinkmann et al., “The making of bispecific antibodies,” MABS, Jan. 2017, 9(2):182-212.
[cited by applicant]
Extended European Search Report in European Application No. 20814936.9, dated Nov. 14, 2022, 7 pages.
[cited by applicant]
Extended European Search Report in European Application No. 20815014.4, dated Nov. 14, 2022, 10 pages.
[cited by applicant]
jhu.technologypublisher.com [online], “Engineered Bispecific Antibodies for Targeted Inhibition of Tumor Metastasis,” Jan. 23, 2019, retrieved from URL<https://jhu.technologypublisher.com/techcase/C15681>, 3 pages.
[cited by applicant]
Tan, “Bispecific Antibodies Targeting of IL-6 and IL-8 Paracrine Signaling Pathway as A Method to Inhibit Tumor Cell Migration,” May 10, 2019, retrieved from URL<https://jscholarship.library.jhu.edu/handle/1774.2/61740>…
[cited by applicant]
Anders et al., “Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer,” Clinical Breast Cancer, Jun. 2009, 9(Suppl. 2):S73-81.
[cited by applicant]
Atwell et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” Journal of Molecular Biology, Jul. 1997, 270(1):26-35.
[cited by applicant]
Boder et al., “Yeast surface display for screening combinatorial polypeptide libraries,” Nature Biotechnology, Jun. 1997, 15(6):553-557.
[cited by applicant]
Carter, “Bispecific human IgG by design,” Journal of Immunological Methods, Feb. 2001, 248(1-2):7-15.
[cited by applicant]
Chuntharapai et al., “Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes,” Journal of Immunology, Dec. 1994, 153(12):5682-5688.
[cited by applicant]
Cochran, “Engineered proteins pull double duty,” Science Translational Medicine, Feb. 2010, 2(17):17ps5, 5 pages.
[cited by applicant]
Costello et al., “New biomarkers and targets in pancreatic cancer and their application to treatment,” Nature Reviews Gastroenterology & Hepatology, Aug. 2012, 9(8):435-444.
[cited by applicant]
Culshaw et al., “What can the periodontal community learn from the pathophysiology of rheumatoid arthritis?,” J. Clin Preiodontol, Mar. 2011, 38(Suppl. 11):106-113.
[cited by applicant]
De Laurentiis et al., “Treatment of triple negative breast cancer (TNBC): current options and future perspectives,” Cancer Treatment Reviews, Nov. 2010, 36(Suppl. 3):S80-S86.
[cited by applicant]
Fan et al., “Bispecific antibodies and their applications,” Journal of Hematology & Oncology, Dec. 2015. 8:130, 14 pages.
[cited by applicant]
Finkelman et al., “Anticytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes,” Journal of Immunology, 1993, 151(3):1235…
[cited by applicant]
Fraley et al., “A distinctive role for focal adhesion proteins in three-dimensional cell motility,” Nature Cell Biology, Jun. 2010, 12(6):598-604.
[cited by applicant]
Frohman et al., “Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer,” Proc Natl Acad Sci USA, Dec. 1988, 85(23):8998-9002.
[cited by applicant]
Fu et al., “Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.” Anticancer Researc…
[cited by applicant]
Giri et al., “The Arp2/3 complex mediates multigeneration dendritic protrusions for efficient 3-dimensional cancer cell migration,” FASEB Journal, Oct. 2013, 27(10):4089-4099.
[cited by applicant]
Gotwals et al., “Prospects for combining targeted and conventional cancer therapy with immunotherapy,” Nature Reviews Cancer, May 2017, 17(5):286-301.
[cited by applicant]
Igawa et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nat. Biotechnol, Nov. 2010, 28(11):1203-7.
[cited by applicant]
International Preliminary Report in Patentability in Appln. No. PCT/US2020/035200, dated Nov. 16, 2021, 7 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2020/035200, dated Aug. 27, 2020, 7 pages.
[cited by applicant]
Jayatilaka et al., “Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration,” Nature Communications, May 2017, 8:15584, 12 pages.
[cited by applicant]
Karagiannis et al., “Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism,” Science Translational Medicine, Jul. 2017, 9(397):eaan0026, 19 pages.
[cited by applicant]
Koerber et al., “An improved single-chain Fab platform for efficient display and recombinant expression,” Journal of Molecular Biology, Jan. 2015, 427(2):576-586.
[cited by applicant]
Kontermann, “Recombinant bispecific antibodies for cancer therapy,” Acta Pharmacol Sin., Jan. 2005, 26(1):1-9.
[cited by applicant]
Krah et al., “Engineering bispecific antibodies with defined chain pairing,” New Biotechnology, Oct. 2017, 39(Pt B):167-173.
[cited by applicant]
Krishnamurthy et al., “Bispecific antibodies for cancer therapy: A review,” Pharmacology & Therapeutics, May 2018, 185:122-134.
[cited by applicant]
Li et al., “Macrophage-Secreted TNFα and TGFβ1 Influence Migration Speed and Persistence of Cancer Cells in 3D Tissue Culture via Independent Pathways,” Cancer Research, Jan. 2017, 77(2):279-290.
[cited by applicant]
Liedtke et al., “Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer,” Journal of Clinical Oncology, Mar. 2008, 26(8):1275-1281.
[cited by applicant]
Martin et al., “Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?,” Nature Reviews Clinical Oncology, Jan. 2017, 14(1):32-44.
[cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nature Biotechnology, Jul. 1998, 16(7):677-681.
[cited by applicant]
Nakashima et al., “Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data,” Modern Rheumatology, Mar. 2014, 24…
[cited by applicant]
Obenauf et al., “Therapy-induced tumour secretomes promote resistance and tumour progression,” Nature, Apr. 2015, 520(7547):368-372.
[cited by applicant]
Orcutt et al., “A modular IgG-scFv bispecific antibody topology,” Protein Engineering Design & Selection, Apr. 2010, 23(4):221-228.
[cited by applicant]
Paudel et al., “The effect of varying the peptide linker length in a single chain variable fragment antibody against wogonin glucuronide,” J. of Biotechnology, 2017, 251, (2017), pp. 47-52, vol.
[cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Engineering, Jul. 1996, 9(7):617-621.
[cited by applicant]
Schott et al., “Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer,” Clinical Cancer Research, Sep. 2017, 23(18):5358-5365.
[cited by applicant]
Singh et al., “Targeting IL-8 signalling to inhibit breast cancer stem cell activity,” Expert Opinion on Therapeutic Targets, Nov. 2013, 17(11):1235-1241.
[cited by applicant]
Spangler et al., “Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression,” Journal of Molecular Biology, Sep. 2012, 422(4):532-544.
[cited by applicant]
Stathis et al., “Advanced pancreatic carcinoma: current treatment and future challenges,” Nature Reviews Clinical Oncology, Mar. 2010, 7(3):163-172.
[cited by applicant]
Steeg, “Targeting metastasis,” Nature Reviews Cancer, Apr. 2016, 16(4):201-218.
[cited by applicant]
Weiner, “Building better monoclonal antibody-based therapeutics,” Nature Reviews Cancer, Jun. 2015, 15(6):361-370.
[cited by applicant]
Wranik et al., “LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies,” Journal of Biological Chemistry, Dec. 2012, 287(52):43331-43339.
[cited by applicant]
Wu et al., “Three-dimensional cell migration does not follow a random walk,” Proc Natl Acad Sci USA, Mar. 2014, 111(11):3949-3954.
[cited by applicant]
Xie et al., “A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis,” Journal of Immunological Methods, Jan. 2005, 296(1-2):95-101.
[cited by applicant]
Yachida et al., “Distant metastasis occurs late during the genetic evolution of pancreatic cancer,” Nature, Oct. 2010, 467(7319):1114-7.
[cited by applicant]
Yang et al., “Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies,” International Journal of Molecular Sciences, Dec. 2016, 18(1):48, 21 pages.
[cited by applicant]
Almagro et al., “Progress and challenges in the design and clinical development of antibodies for cancer therapy,” Frontiers in immunology, Jan. 4, 2018, 8:1751.
[cited by applicant]
Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody Vh Cdr 2: a means of minimizing B cell wastage from somatic hypermutation?” J Immunol, May 1, 1996, 156(9):3285-91.
[cited by applicant]
Chiu et al., “Antibody structure and function: the basis for engineering therapeutics,” Antibodies, Dec. 3, 2019, 8(4):55.
[cited by applicant]
David et al., “The IL-8/IL-8R axis: a double agent in tumor immune resistance,” Vaccines, Jun. 24, 2016, 4(3):22, 1-15.
[cited by applicant]
IMGT.org [online], “Correspondence between the IMGT unique numbering for C-Domain, the IMGT exon numbering, the Eu and Kabat numberings: Human IGHG,” Jun. 8, 2016, Retrieved on Aug. 9, 2017, Retrieved from URL <http://w…
[cited by applicant]
Kim et al., “Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells,” Oncology letters, 2015, 9(5):2283-8.
[cited by applicant]
Marvin et al., “Redesigning an antibody fragment for faster association with its antigen,” Biochemistry, Jun. 17, 2003, 42(23):7077-83.
[cited by applicant]
Raimondo et al., “Profile of sarilumab and its potential in the treatment of rheumatoid arthritis,” Drug Design, Development and Therapy, May 24, 2017, 1593-603.
[cited by applicant]
Rudikoff et al, “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences, Mar. 1982,79(6):1979-83.
[cited by applicant]